Very recently, we demonstrated that quercetin was able to sensitise leukaemic cells isolated from CLL patients when associated with recombinant TRAIL (rTRAIL) or anti-CD95 (Russo et al, 2010). This evidence concerns the gene FAS and B-cell chronic lymphocytic leukemia.